Alessandra Iurlo

Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

Roberto Marchioli, Guido Finazzi, Giorgina Specchia et al. · New England Journal of Medicine · 2012 · 820 citations · Full text

Medicine, Hematology, Pharmacotherapy +10

Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study

Silvia Mori, Elisabetta Vagge, Philipp le Coutre et al. · American Journal of Hematology · 2015 · 209 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

Medicine, Hematology, Pharmacology +9

Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the<i>SEC23B</i>gene

Paola Bianchi, Elisa Fermo, Cristina Vercellati et al. · Human Mutation · 2009 · 180 citations

Life Sciences, Genetics, Molecular Genetics +17

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio et al. · Cancer · 2019 · 149 citations · Full text

Medicine, Hematology, Pharmacology +10